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Background: Investigational and marketed drugs for the treatment of multiple myeloma
(MM) are associated with a range of characteristics and uncertainties regarding long term
side-effects and efficacy. This raises questions about what matters most to patients living
with this disease. This study aimed to understand which characteristics MM patients find
most important, and hence should be included as attributes and levels in a subsequent
quantitative preference survey among MM patients.
Methods: This qualitative study involved: (i) a scoping literature review, (ii) discussions
with MM patients (n= 24) in Belgium, Finland, Romania, and Spain using Nominal Group
Technique, (iii) a qualitative thematic analysis including multi-stakeholder discussions.
Results: MM patients voiced significant expectations and hopes that treatments
would extend their lives and reduce their cancer signs and symptoms. Participants
however raised concerns about life-threatening side-effects that could cause permanent
organ damage. Bone fractures and debilitating neuropathic effects (such as chronic
tingling sensations) were highlighted as major issues reducing patients’ independence
and mobility. Patients discussed the negative impact of the following symptoms
and side-effects on their daily activities: thinking problems, increased susceptibility
to infections, reduced energy, pain, emotional problems, and vision problems. MM
patients were concerned with uncertainties regarding the durability of positive treatment
outcomes, and the cause, severity, and duration of their symptoms and side-effects.
Patients feared short-term positive treatment responses complicated by permanent,
severe side-effects and symptoms.
Conclusions: This study gained an in-depth understanding of the treatment and
disease-related characteristics and types of attribute levels (severity, duration) that
are most important to MM patients. Results from this study argue in favor of MM
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drug development and individual treatment decision-making that focuses not only on
extending patients’ lives but also on addressing those symptoms and side-effects
that significantly impact MM patients’ quality of life. This study underscores a need
for transparent communication toward MM patients about MM treatment outcomes
and uncertainties regarding their long-term efficacy and safety. Finally, this study may
help drug developers and decision-makers understand which treatment outcomes and
uncertainties are most important to MM patients and therefore should be incorporated
in MM drug development, evaluation, and clinical practice.
Keywords: multiple myeloma, patient preferences, nominal group technique, qualitative research, attributes, drug
development, regulatory benefit-risk assessment, health technology assessment
INTRODUCTION
Patient preference studies use qualitative and quantitative
methods to understand which treatment and disease-related
characteristics (efficacy outcomes, side-effects, and symptoms)
are important to patients, how important they are to patients,
the trade-offs patients are willing to make between these
characteristics, and how preferences may vary according to
individual patient characteristics (1–3). Stakeholders involved
in drug development and evaluation—such as drug developers,
regulators, Health Technology Assessment (HTA) bodies and
payers—have acknowledged the potential value of using patient
preference studies to inform their respective decisions (4–6).
More specifically, patient preference studies could: (i) reveal
the patient perspective on unmet treatment needs in early drug
development, (ii) inform the development of patient reported
outcome measures and the selection of clinical trial endpoints,
(iii) help understand which are the key favorable and unfavorable
effects and uncertainties in regulatory benefit-risk assessment,
(iv) quantify the relative importance of treatment characteristics
in HTA and payer decisions, and (v) inform the development
of decision aids used in shared individual treatment decision-
making between patients and clinicians (1, 4–18).
On the regulatory level, the European Medicines Agency
(EMA) and the US Food and Drug Administration (FDA)
intend to systematically include preference studies in regulatory
benefit-risk assessment (4–6, 19–21). Mirroring the FDA’s
efforts toward guidance surrounding patient preference studies,
the EMA aims to develop guidance on appropriate methods
for patient preference study design, conduct, analysis, and
presentation for regulatory purposes, to ensure that high
quality methodologies are applied (4). A reflection paper by
the EMA details opportunities for the development of new
guidelines by the International Council for Harmonization
of Technical Requirements for Pharmaceuticals for Human
Use (ICH). These guidelines will aim to provide a globally
harmonized approach to inclusion of the patient’s perspective
in a way that is methodologically sound and sustainable for
both regulated industry and regulatory authorities (22). From
the HTA/reimbursement perspective, the National Institute for
Health and Care Excellence (NICE) argues that patient preference
studies could be used to inform the selection of clinical
trial endpoints, and inform regulatory benefit-risk assessment,
echoing the EMA’s viewpoints (23). In addition, NICE sees a
role in preference studies for informing their HTA assessment
alongside other types of clinical and economic evidence (23,
24). Similarly, drug developers more often include preference
studies in their drug development plans, regulatory, and HTA
submissions (25).
However, while stakeholders have expressed an interest
in using patient preference studies to inform their respective
decisions, previous research has revealed that more evidence-
based preference study development is needed to build
methodological and practical knowledge and address
uncertainties regarding the design, conduct, and use of patient
preference studies (1, 10, 26). In response to this, several research
projects, such as the IMI PREFER project, have been initiated by
drug developers, academic researchers, as well as HTA bodies
and regulatory agencies. Such projects aim to investigate how
patient preference studies could inform decision-making, and
how such studies could be designed to meet methodological
requirements of stakeholders involved in these decisions (27–29).
A crucial initial step in patient preference studies is the
use of qualitative data collection for identification of the key
attributes and levels of importance to patients for inclusion in
the subsequent quantitative phase of the study. Attributes are
the key aspects that impact patients’ choices toward treatments
and include benefits, risks or other clinical and non-clinical
aspects that influence the desirability or acceptability of medical
interventions (30). Therefore, attributes of key importance to
patients may align decision-making with patient’s perspectives
both in the individual treatment decision-making context (16–
18), as well as in decision-making regarding drug development,
authorization, and reimbursement. Attribute levels are the
values or categories used to characterize the performance of a
treatment (31). As qualitative methods provide in-depth and
meaningful information from patients, their use is recommended
for the development of attributes and levels. Qualitative methods
with patients may reduce the potential for misspecification of
attributes through overreliance on the views of experts and
researchers (27, 28). In doing so, using qualitative research
for the development of attributes and levels may improve
the validity of subsequent quantitative preference surveys.
Therefore, by combining both qualitative and quantitative
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methods in preference studies, the data collected on patient
preferences is likely to be more comprehensive, meaningful,
and a valid interpretation of the true patient perspective (32).
However, qualitative preference research that informs subsequent
preference surveys remains underreported, creating uncertainty
regarding the methodological and practical application of these
methods and results for informing subsequent quantitative
preference surveys.
Eliciting preferences from Multiple Myeloma (MM) patients
is especially valuable in view of the rapid development of
various novel MM treatments with substantial effects on survival,
toxicity, efficacy, and related long-term uncertainties. Among
patients and various stakeholders, the impact of these treatments
on patients’ lives, attitudes and choices toward treatments is
largely unknown. MM is the second most frequent hematological
malignancy after non-Hodgkin lymphoma, accounting for 1%
of all cancers and 10% of blood cancers (33, 34). MM
is characterized by a proliferation of plasma cells in the
bone marrow, typically accompanied by the secretion of
monoclonal immunoglobulins (M-proteins or paraproteins)
(35). This proliferation causes symptoms such as skeletal damage,
hypercalcemia, renal insufficiency, anemia, and infections (36).
Because MM disrupts the normal functioning of the bone
marrow, damages the bones and causes kidney failure, MM
is considered to be a debilitating and life-threatening disease.
Despite several drugs being available, MM has been labeled an
incurable disease and only half of the diagnosed patients live
longer than 5 years (33).
New MM treatments are currently being developed that have
different side-effect profiles, mechanism of action, and efficacy
from those currently available. More specifically, innovative
treatments currently under development, such as bispecific T-cell
engagers and chimeric antigen receptor therapies (CAR-T), have
shown to be efficacious but also associated with severe risks such
as cytokine release syndrome (an acute systemic inflammatory
syndrome characterized by fever andmultiple organ dysfunction)
and neurotoxicity’s (such as encephalopathy, aphasia, delirium,
tremor, and seizures) (37). Differences between treatments, based
on varying benefits and risks, raise the question about how MM
patients value these treatment aspects. Furthermore, decisions
surrounding MM treatment can be labeled as “preference
sensitive” decisions where: (i) multiple treatment options exist
and there is no option that is clearly superior for all patients; (ii)
the evidence supporting one option over others is considerably
uncertain or variable and (iii) patients’ views about the most
important benefits and acceptable risks of a treatment vary
considerably within a population and may differ from those of
healthcare professionals (20).
Therefore, given the lack of valid, meaningful, and
comprehensive qualitative research on MM patient preferences,
the present study aimed to understand which characteristics MM
patients find most important, and hence should be included as
attributes and attribute levels in a subsequent preference survey.
By pursuing these objectives, this study derives experience-
based learnings regarding the design, conduct and analysis of
qualitative research aiming to develop attributes and levels for
inclusion in subsequent preference surveys in the context of drug
development and evaluation. Such methodological learnings
may foster the development of a standardized approach to be
used by all stakeholders across disease areas, and serve to include
a validated patient preference framework for drug development,




The Patient Preferences in Benefit-Risk Assessments during
the Drug Life Cycle (PREFER) project is a 6-year public
private partnership that received funding from the Innovative
Medicines Initiative (IMI) 2. This project seeks to guide
drug developers, regulatory authorities, and HTA bodies
(including reimbursement agencies and payers) on how and
when patient preference studies should be performed and
how the results can be used to inform decision-making.
The initial phase of the PREFER project included discussions
with a broad representation of stakeholders such as patients,
patient organizations, regulatory authorities, HTA bodies, and
reimbursement agencies that expressed interest in preference
studies, and revealed the need to further explore and test
preference methods (1, 7, 9, 10, 26). Therefore, this study has
been developed in the context of recommendations formulated
by IMI PREFER. The results of PREFER are expected to lead
to changed practices, in that stakeholders will routinely assess
whether a preference study would add value at key decision
points in the medicinal product life cycle and, if so, implement
patient preference studies according to the PREFER project
recommendations (38).
Study Design
This study was designed and executed according to: (i) the
recommendations on qualitative data collection and analysis
methods for initial attribute development (39, 40); (ii) the
steps describing attribute and level development in health
preference research formulated by Bridges et al. (41); (iii)
the criteria described by Hensher et al. (42) regarding what
constitutes “good” attributes; (iv) the framework method for
thematic analysis described by Lacey and Luff (43) and (v)
the recommendations for reporting the results of a qualitative
preference study (40).
Following recommendations by Hollin et al. (40), Coast et al.
(39), and Bridges et al. (41), this paper describes: (i) the rationale
for the methodological steps and choices taken to develop
attributes and levels; (ii) a detailed description of the included
participants; (iii) details regarding the practical steps and setting
of the qualitative study including the recruitment, discussion
guides, involved researchers; (iv) details of the subsequent steps
including the transcription, translation, and analysis and (v) the
results of the qualitative study.
Study Phases
To understand the key characteristics of importance to MM
patients, a qualitative study was completed in three phases
(Figure 1). Several preference studies attest to the usefulness of
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FIGURE 1 | Design of the qualitative study consisting of three phases: (i) a scoping literature review, (ii) discussions with MM patients using Nominal Group Technique
(NGT), and (iii) analysis involving multi-stakeholder discussions with patients, patient organizations, clinicians, and preference experts. The subsequent quantitative
study will be conducted using the attributes and levels identified in the present qualitative study. MM, Multiple Myeloma; NGT, Nominal Group Technique; EMA,
European Medicines Agency.
qualitative methods with patients and advocate for the use of
literature reviews to inform the development of attributes and
levels (31, 39–41, 44). Therefore, this study involved three phases,
whereby each phase informed the subsequent phase (Figure 1):
(i) a scoping literature review, (ii) discussions with MM patients
using Nominal Group Technique (NGT), and (iii) a combined
quantitative and qualitative thematic analysis involving multi-
stakeholder discussions with patients, patient organizations,
clinicians, and preference research experts.
Phase 1: Scoping Literature Review
The scoping review aimed to identify potential relevant
characteristics (treatment outcomes, symptoms, and side-effects)
for grading in subsequent patient discussions using NGT. Bridges
et al. (41) recommend that attribute development should be
supported by evidence on the potential range of preferences
and values that respondents of the preference survey may
hold. Therefore, the list of treatment characteristics that was
used for the NGT (Appendix 1, section 3) was informed by a
scoping literature review of: (i) the attributes and key results
of published preference studies conducted among MM patients
(Appendices 2, 3), (ii) favorable and unfavorable effects of MM
treatments already assessed by EMA that includes characteristics
of treatments already being prescribed to patients (Appendices 4,
5) and (iii) primary and secondary endpoints and adverse
events reported in phase 3MM clinical trials in the European
Union (EU) to ensure the attribute list captured treatment
characteristics of therapies in development; this was done so that
in the discussions patients would be able to discuss potential
“future” treatment outcomes and side-effects, even though they
had not yet experienced them (Appendices 6, 7).
Searches for published preference studies amongMM patients
were conducted in PubMed and Embase (see Appendix 2 for
the selection procedure). The search queries included free text
terms in title and/or abstract and Medical Subject Headings
(MeSH) and included synonyms for the following two concepts:
“multiple myeloma” AND “patient preferences.” The database
searches yielded 250 publications. Publications were included
if they reported preferences from MM patients. Conversely,
studies were excluded if: (i) preferences were not elicited
from patients (e.g., only from caregivers or clinicians); (ii) no
preference method (qualitative/quantitative) was applied; (iii)
no preferences were reported (e.g., study protocols) and (iv)
the study focused on: patient preferences for whether or not
patients are willing to participate in decision-making, patient
preferences for remote monitoring, or if the study investigated
whether patients do or do not want to receive information. The
results were screened in a 2-fold manner. First, the title and
abstract were screened based on the in- and exclusion criteria.
Afterwards, the full text was reviewed against the same criteria.
From the database searches, 15 publications were included in the
review. Subsequently, the following information was extracted
(Appendix 2): (i) first author and year; (ii) type of publication;
(iii) research objective; (iv) participants; (v) preferencemethod(s)
used; (v) attributes/items/factors identified or used in the study
and (vi) key results. To develop a final list of characteristics for
grading (Appendix 1), the treatment characteristics that emerged
from the scoping review were combined and then grouped with
Frontiers in Medicine | www.frontiersin.org 4 July 2021 | Volume 8 | Article 686165
Janssens et al. Patient Preferences for Multiple Myeloma Treatment
both the characteristics of treatments being prescribed to patients
(Appendices 4, 5) and with the characteristics of treatments
included in phase 3MM clinical trials (Appendices 6, 7).
Phase 2: Discussions With Multiple Myeloma
Patients Using Nominal Group Technique
Objectives and Rationale
Phase 2 aimed to: (i) understand which characteristics, including
those identified in phase 1, were most important to MM patients,
and hence should be included as attributes in the subsequent
preference survey that quantifies the relative importance of these
attributes; (ii) understand the factors and dimensions influencing
patient choices; what determines whether patients would take,
not take, or discontinue a certain treatment, and hence should
be included as attribute levels and (iii) understand the language
patients use to describe symptoms, treatment outcomes, and
side-effects, and hence should be the language used to describe
the attributes and levels.
To reach these objectives, discussions with 24MM patients
in Belgium, Finland, Romania, and Spain were held (see
“Recruitment, study population, and setting” for a rationale
for including these countries). The discussions used NGT,
a type of focus group discussion methodology, that asked
patients to rank and reach consensus on the most important
characteristics (see “step-by-step procedures”). While standard
focus group discussions use open discussion throughout, NGT
is a consensus focus group methodology that differs from
standard focus group discussions. In addition to providing a
format for open discussion, NGT includes a structured four-
stage process and a methodology for capturing participant
responses and with inclusion of prioritization and participant’s
individual and collective perspectives. NGT is specifically suited
to identify attributes due to its structured approach and grading
methodology; the grading allows researchers to select and
understand which treatment characteristics are most important
and hence should be used for developing the attributes in
the subsequent preference survey. Furthermore, NGT has the
advantage over other qualitative consensus methods as it ensures
groups to reach consensus in a short period of time (39).
Patient Involvement and Piloting
In addition to inclusion in NGT discussions, MM patients,
and MM patient organizations were involved in all steps of
research.MMpatients and/orMMpatient organizationmembers
provided written and oral feedback on all patient materials
including the information sheet, informed consent, answer
sheet (including explanatory parts), and questions. All patient
documents were first translated by a professional translation
company to the native language of participants, and subsequently
revised for accuracy and understandability by patients, patient
organizations, and clinicians.
Recruitment, Study Population, and Setting
Hematologists performed the recruitment at their respective
hospitals and were asked to ensure a diverse patient population
was invited to participate in the discussions. It was anticipated
that several individual patient characteristics—such as socio-
demographics, disease stage and treatment experience—could
influence participants’ opinions and rankings. The goal was to
ensure that the attributes and levels identified in this study were
not directed only to patients with a specific treatment exposure,
disease history, age or country of origin; but rather toward all
patients along the MM spectrum. Therefore, during recruitment,
heterogeneity in terms of treatment experience, disease stage,
age, and country was introduced as much as possible. During
sampling, hematologists used the following inclusion criteria: (i)
patients diagnosed with symptomatic MM; (ii) patients ability to
understand the language to be used in the discussion and (iii)
patients ability to participate in the discussion.
Recruitment sought to include between 5 and 7MM
patients across four countries: Belgium, Finland, Romania, and
Spain. These countries were included to account for potential
differences in patient characteristics and, as mentioned above,
to increase heterogeneity and thereby ensure the identified
attributes and levels were not only relevant to a particular type
of patient. While McMillan et al. (45) describes that most NGTs
include between 2 and 14 participants, a maximum of seven
is recommended as a much larger number would delay the
phased process of the NGT discussion, which aims to reach
consensus in a short time span (up to 2 h). Therefore, minimally
5 and maximally 7 patients were included in each country.
There are no guidelines that define how much data, and hence,
participants should be included in qualitative research (30).
Instead, saturation is often used to define when data collection
can stop (30, 32, 46). Saturation is defined as the point when
“no new information or themes are observed in the data” (47).
Hennink et al. (48) state that when the goal is to identify “core”
issues, few discussions could be enough to reach data saturation,
and some studies have reached saturation after 4–6 focus groups
(30, 32, 46). Since the goal of our study was to identify core,
overarching attributes, it was expected that data saturation could
be achieved by including between 5 and 7MM patients in four
countries (n = 24 across all countries). Following qualitative
data collection, it appeared that the same themes of treatment
attributes were observed across different countries. Hence, it was
decided that saturation was reached and no additional data was
needed to inform the attributes and levels.
The discussions were organized at a location convenient
for participants, between April and November 2020, and
considered the implications of the coronavirus (COVID-
19) pandemic; discussions were organized either face-to-face
or online, according to the preference of participants and
recommendations set-out by hospitals regarding patient contact.
Step-by-Step Procedures
As part of the recruitment process, an invitation letter was
sent to those expressing interest in the study and fulfilling
inclusion criteria (see “Study recruitment, population and
setting”). Potential participants were contacted to verify their
willingness to participate and if so, arrange the practicalities of
the discussion. The information sheet and informed consent was
provided to participants in their own language. Both documents
were provided to participants prior to the discussion, and the
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informed consent form was signed by all participants before
the discussion. As preparation for the discussion, participants
were invited to complete an answer sheet containing three
sections: (i) participants’ background characteristics, including
Chew’s Set of Brief Screening Questions (Appendix 1, section
1); (ii) open questions probing for treatment characteristics of
importance (Appendix 1, section 2) and (iii) a grading exercise
asking patients to grade the treatment characteristics identified
in the scoping literature review from 1 (= not important at
all) to 5 (= very important) (Appendix 1, section 3). The NGT
discussion consisted of the following four steps (Appendix 8): (i)
idea, (ii) round robin, (iii) clarification and finalization of the list
of attributes, (iv) grading and consensus.
Each discussion was conducted by a person fluent in the
native language of the participants. The discussions lasted
around 90min, were voice-recorded and included a break of
∼10min. The audio-recordings were transcribed verbatim by a
professional transcribing company in the original language and
then translated to English. To ensure patients’ opinions were
accurately reflected in the subsequent analysis and development
of the attributes and levels, the moderators were closely involved
in the subsequent analysis (see phase 3).
Phase 3: Analysis Involving Multi-Stakeholder
Discussions
In the final phase, a combined quantitative descriptive analysis
of patients’ rankings and iterative qualitative thematic analysis
of the discussion transcripts was used to determine overarching
themes of prioritized treatment characteristics relevant to all
participating patients, regardless of their treatment exposure,
disease history, age, or country of origin.
Quantitative Analysis
Participants’ self-reported characteristics, as obtained through
sections 1 and 3 of the answer sheet (Appendix 1) were analyzed
descriptively using Microsoft Excel. Patient characteristics were
tabulated for all patients together and for each of the questions
asked in Appendix 1. ANOVA and Fischer exact tests were
performed to investigate statistically significant differences
between groups of participants and countries. Health literacy was
determined using Chews’ set of brief screening questions (49).
The grades for the characteristics were calculated per country
to derive rank orders and averages at country level. To obtain a
final rank of the themes pertaining to treatment characteristics,
the averages for each theme were calculated by combining the
previously calculated averages obtained in the four countries.
Qualitative Analysis
The qualitative analysis took into account the following criteria
and best practices for attribute and level development; therefore,
attributes and levels should be:
• Relevant to patients and/or policy-makers, plausible, capable
of being traded, unambiguous, distinctly different from
other included attributes, comprehensive, and of salience to
respondent’s decisions (39, 40);
• Inclusive of all aspects that might be important for an
individual in coming to a decision (28, 39);
• Not too close to the latent construct such as overall quality of
life (28);
• Not have such a large impact on decisions that large numbers
of respondents of the quantitative survey make no errors
when deciding, such as overall happiness with the alternative
treatments presented in the preference survey (28);
• Not intrinsic to a person’s personality, these aspects need
to be considered in analyzing and describing preference
heterogeneity (28);
• Developed through an iterative, constant comparative analysis
approach to continually modify and extend the attributes
and levels to ensure that all key aspects can be incorporated
through this modification (28);
• Inclusive of all aspects that might be important for an
individual in coming to a decision, as ignoring important
attributes and levels may bias findings; and qualitative
methods to determine overarching attributes must encompass
key themes combined with piloting to avoid bias (28);
• Created through a process consisting of conceptual
development where the attributes and levels are identified,
followed by refinement of language to ensure the intended
meaning is conveyed toward the participants in the preference
survey (28);
• Inclusive of all characteristics that potentially characterize
the alternative treatments presented to participants in
the preference survey, with consideration that some
characteristics may be excluded if the alternative treatments
are not plausible to subjects (39).
The framework method by Lacey and Luff (43) was used
to develop overarching themes that capture prioritized
characteristics for inclusion as attributes and levels (Table 1). The
analysis was performed by a multi-stakeholder team including
patients, patient organizations, clinicians, and academic
preference research experts. Discussions with patients and
patient organizations specifically sought to confirm whether the
themes captured the most relevant characteristics for inclusion
as attributes and levels, and whether the results described
accurately represented their views. In particular, MM patients
and/or MM patient organization members provided written
and oral feedback on the relevance, comprehensiveness, and
understandability of the themes of characteristics for inclusion
as attributes and levels. Discussions with clinicians were held
to confirm the clinical plausibility of the attributes and levels.
Also, to ensure adherence to rules for attribute and level
development, preference expert input was included. Finally, the




In total, 24MM patients (6 per country, 4 countries) agreed to
participate. The average response rate across countries was 46%.
Reasons for not participating were: (i) research topic was not
in their field of interest; and (ii) not willing to communicate in
groups. The mean age across countries varied between 60 and 65
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TABLE 1 | Iterative steps of the qualitative thematic analysis using the framework method.
1. Familiarization The transcripts were thoroughly read and re-read and the audio-recordings were listened to again if a certain part
of the transcript was unclear. The margins of the transcripts were used to write down analytical notes, thoughts or
impressions (e.g., when participants expressed exceptionally strong or contrasting views). Discussions among the
moderators on preliminary findings sought to confirm whether they interpreted the discussions in the same
manner.
2. Identifying a thematic framework A list of overarching themes capturing prioritized treatment characteristics was developed based on the views
expressed by patients during the discussions, in their answer sheet, and the ranked list of characteristics and
explanations. This list was transported to NVivo (11th edition, QSR International) for coding.
3. Coding Literal quotations (text) in the transcript and answer sheets were attached to each of the themes, describing what
participants stated about these themes (coding). Throughout the coding process, it was assessed whether the list
of themes and their explanations covered what participants said. If not, modifications were made to the name of
the theme. Discussions among the team (see below) sought to modify and reach consensus about the themes.
The end result was the final list of themes, each with a brief explanatory description of their meaning including
examples to further explain the theme (see below).
4. Charting NVivo was used for charting (summarizing) the data per attribute.
5. Mapping and interpretation Several meetings among a multi-stakeholder team were organized to discuss the qualitative findings (the final list
of themes) together with the characteristic scorings of the quantitative analysis. During these meetings, consensus
was reached about the final list of attribute themes and associated levels to take forward to the quantitative survey.
An iterative, constant comparative analysis approach was used to allow for continuous modifications and extensions of the themes to ensure that all key aspects of importance to
patients could be incorporated.
years (M: 61 across all countries, range 46–73). Most participants
had a Masters’ degree (42%) followed by a Bachelor (25%) or
High school degree (25%). Most participants (58%) described
their activity level as “not my normal self, but able to be up and
about with fairly normal activities” (fair mobility), followed by
“normal, without any limitations” (no limitations; 25%) and 13%
identified themselves as “not feeling up to most of the things, but
in bed of chair less than half of the day” (sedentary) (Appendix 9).
Most participants (88%) did not live alone at the time of the
discussion. Many participants were employed (50%) or retired
(42%). The median participant received their MM diagnosis at
the age of 55. Participants were heterogeneous in terms of how
long they had received their diagnosis; ranging between 18 years
ago to the same year of the discussion.
Nearly all patients (96%) were on treatment at the time
of the discussion. Across countries, participants were
most frequently treated with proteasome inhibitors (PIs)
(50%), immunomodulating agents (IMiDs) (46%) and
steroids (46%), followed by supportive treatments (33%,
e.g., calcium and vitamin D supplements, pain medication)
and monoclonal antibodies (mAbs) (21%). Participants
were previously treated with an average of three different
regimens (one treatment line referring to one drug or a
combination of drugs given for a specific time duration)
at the time of the discussion and the number of treatment
lines across participants ranged between one and seven
previous treatment lines. Fifty-eight percentage of patients
indicated that they suffer from at least one of the following
chronic health problems: heart rhythm disorders, prostate
hypertrophy, hypertension, hypothyroidism, glaucoma, renal
insufficiency, diabetes, and arthritis. The vast majority (83%)
of participants indicated that they were not in frequent
contact with a patient organization. Across countries, the
majority of participants had a high (46%) or moderate (42%)
health literacy.
Statistical tests (Fischer exact and ANOVA) revealed no
significant differences between the patient groups of the different
countries, regarding their age (F = 1.61, p = 0.22), gender
(X2 = 1.90, p = 0.81), education (X2 = 8.01, p = 0.62), work
status (X2 = 10.76, p = 0.05), contact with patient organizations
(X2 = 3.72, p= 0.22), other chronic health problems (X2 = 6.73,
p = 0.08), health literacy (X2 = 2.99, p = 0.93), and number of
treatment lines (F = 2.64, p= 0.09).
However, there were statistical differences in activity level
(X2 = 10.78, p = 0.03), living situation (X2 = 4.70, p = 0.04),
enrolment in clinical trial (X2 = 8.33, p = 0.04), and years since
diagnosis (F = 3.28, p = 0.04). In particular, the Finnish group
had a better activity level than the other groups; 67% of the
participants considered their activity level as “normal, without
any limitations.” Further, only 50% of the Finish group was not
living alone vs. 100% in the other countries. Regarding clinical
trial enrolment, nearly all Finnish participants were currently
(50%) or previously (30%) enrolled in a clinical trial, as opposed
to the other countries, where nearly equal distributions were
observed (42% yes vs. 54% no). Spanish participants were more
recently diagnosed with MM (M: 1 year since diagnosis) vs.
Belgian participants (M: 9 years) (see Appendix 9 for a full
overview of participants’ characteristics).
Themes Capturing Prioritized
Characteristics for Inclusion in Attributes
and Levels
Patients across countries and with varying disease and treatment
experiences reached consensus on the importance of the
following eleven attribute themes (outcomes, side-effects,
and symptoms): life expectancy, life-threatening side-effects,
treatment response, mobility problems, thinking problems,
infections, reduced energy, pain, emotional problems, eating
and digestive problems, and vision problems. These attribute
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themes are categorized below into: (i) favorable effects: treatment
outcomes considered desirable or beneficial, and (ii) unfavorable
effects: side-effects and symptoms negatively impacting patients’
life expectancy and/or quality of life.
Regarding the types of attribute levels, patients highlighted
the importance of specifying the duration and severity of the
treatment effects as it would determine their treatment choices.
In particular, patients expressed the fear of short-term positive
treatment outcomes and long-term negative effects. Conversely,
several expressed that transient side-effect are more acceptable.
Patients were also afraid of symptoms and side-effects that
are so severe, in that sense that they would hamper them in
performing their daily activities. Therefore, severity and duration
were specified as attribute levels.
Patients highlighted the importance of both life expectancy
and quality of life: “as many years with the best quality of
life as possible” and highlighted that the balance between the
treatments’ effect on their life expectancy and quality (would)
determine their individual treatment choices: “I would reconsider
continuing treatment) if the impact on daily life is so great
that the quantity of life (years) becomes less important than the
quality of life.” Participants’ willingness to accept a reduction
in quality of life in return for an increased life expectancy
differed across participants and depended on their individual
situation and personal attitudes. In particular, participants who
were older, had undergone more treatments, and had no young
children, seemed to place more importance on quality of life
related attributes (such as pain) rather than life expectancy, and
vice versa. However, on average, life expectancy was graded the
highest by MM patients, followed by side-effects and symptoms
that significantly impact patients’ life expectancy and/or quality
of life.
Favorable Effects: Treatment Outcomes Considered
Desirable or Beneficial
Life Expectancy
Increasing life expectancy was on average, the most important
treatment outcome for patients across the four countries:
“Lengthened life span is of course most important,” “I think that
the most desirable effect of myeloma treatment would be longer life,
and, I don’t know whether this needs any justification as to why.”
Depending on their personal context, participants described that
they want to be there to see their children grow up, take care
of their loved ones and be professionally active. MM patients
described the negative psychological impact of the uncertainty
of how long they had to live: “the sword of Damocles hanging
over me.”
Treatment Response
Participants voiced significant expectations and hopes that
treatments would work to successfully fight their cancer and
extend their lives. Any improvement or positive treatment
outcome was considered to be important: “Any improvement
would be welcome.” Participants agreed that they want a
treatment that will have lasting improvements in any signs
and symptoms associated with their cancer and removal of
cancer cells.
Many patients hoped for a complete remission, i.e., a complete
removal of all cancer signs. Several participants acknowledged
that cure—a complete and permanent elimination of all cancer
cells—is not achievable with current treatments. However, to be
cured permanently, was considered to be the ultimate treatment
goal by some patients: “I am hoping that by continuing the
treatment I will get cured.” Several also described that if the
treatment would cure them, they would be willing to accept even
those treatment side-effects that they had described as the worst
treatment effects.
Positive laboratory and imaging tests were recognized as
important indicators of a stabilization of cancer progression.
The knowledge and interest of some participants regarding MM
biomarkers was remarkable; several participants shared detailed
experiences regarding their test results and the importance
of positive laboratory and imaging findings. Patients also
highlighted that test results impact their psychological well-
being; despite burdensome symptoms and side-effects, positive
results give patients hope and motivation to carry on: “To
get that M-component to fall or become invisible; these are
such improvements that they do make even some more difficult
side-effects acceptable.” The importance of a sustained positive
treatment response (inclusive of reduction in symptoms) was
also noted.
Unfavorable Effects: Side-Effects and Symptoms
Negatively Impacting Patients’ Life Expectancy
and/or Quality of Life
Life-Threatening Side-Effects
Patients were afraid of serious side-effects that are life-
threatening and could (permanently) damage other (vital)
organs: “Of course, any life-threatening side-effects (. . . ) would
make me think twice (. . . ), as the side-effects would then be
worse than the illness.” The following side-effects were raised:
developing another cancer, stroke, heart failure, septic shock,
and severe bleeding. Among these, the fear and uncertainty
of developing another cancer was highlighted multiple times:
“You also have psychological consequences, the fear of a
secondary cancer.”
Mobility Problems
Participants discussed which physical symptoms and side-
effects significantly reduce their independence and “control
their life.” In particular, bone fractures were highlighted as
major issues reducing patients’ ability to move, and hence,
reducing their independence and overall quality of life. Regarding
bone fractures, several patients expressed the desire for an
improvement in their “bone weakness” or a stabilization of their
bone destruction. Aside from the negative physical impact of
bone weakness, patients also described the negative psychological
impact of these issues; the fear of being active due to a high risk
of fractures: “So it’s the fear to try to do something and get a
fracture, like that, break a bone, that fear.” Vice versa, patients
argued that an increased ability to move would improve their
psychological well-being. Some participants added that bone pain
could be both due to the disease as well as due to treatment
with bisphosphonates. The importance of the duration and
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severity of their mobility problems was also stressed; while some
patients expressed to be willing to accept temporary immobility,
permanent immobility—requiring a rollator or wheelchair—was
considered to be unacceptable by many. Patients also expressed
the burden of the uncertainty of the duration of these problems:
“When will I be able to ski? Will I ever be able to ski? To do the
things we did before.”
Symptoms associated with nerve damage and subsequent
mobility problems were also discussed extensively. These issues
commonly occur in extremities [feet, legs (calves), hand, fingers]
and are particularly burdensome because they limit patient
movement. Examples of these symptoms are: chronic (strange)
sensations or tingling (“pins and needles”); over-sensitivity of
the skin and bruises; numbness or reduced physical sensations
(i.e., “sleeping” feet, fingers, and toes). Furthermore, participants
described weakness or stiffness in feet and legs causing instability:
“Not having tingling in the feet. It makes walking difficult for
me, the feeling of always having numb feet is very unpleasant.”
Participants argued how improvements in these problems would
be highly welcome: “If something was found that would improve
the whole tingling sensation that has become chronic.” Participants
hoped these effects would improve once the treatment is stopped.
Several feared constant mobility problems related to neuropathic
symptoms and raised the uncertainty related to the duration
of these issues. Those participants who themselves did not
experience permanent side-effects, admitted to the psychological
trauma of watching and knowing other MM patients who were
permanently immobile and dependent on others.
Thinking Problems
Patients expressed fear of cognitive changes that would affect
their daily mental activities such as: difficulties to think clearly,
concentrate and pay attention (e.g., difficulties in reading a
book, watching TV), memory loss, lower levels of consciousness,
hallucinations (seeing, feeling, or sensing things that seem
real but are not), dizziness, and confusion. Patients feared
permanent and severe thinking problems that may reduce their
independence, such as permanent memory loss (dementia) and
definitive forgetfulness. Patients both speaking from experience,
as well as those who had not yet experienced these symptoms,
stated that such problems may prevent them from performing
their professional and daily activities: “Anything that could affect
the brain or ability to concentrate (. . . ) would really be a problem
and would mean that I would have to give up my job which I
really like and which forms a big part of my life.” Patients also
felt that thinking problems may also result in a change to their
identity, and negatively affect how they interact with others.
Patients described how difficult it would be to have both thinking
problems and mobility problems: “So then there is not much
left because you cannot read a book, (. . . ) you cannot even do
something else with your thoughts. And then in fact you can hardly
do anything anymore.” One patient also described how a lack of
ability to think—“a complete loss of thinking”—makes it difficult
to plan anything in the future.
Infections
Patients discussed the negative consequences, both physically and
mentally, of having an increased susceptibility to infections: “so
we are just afraid of infections, because our resistance is reduced”
(. . . ) especially in view of the COVID-19 pandemic: “Especially
now in the corona crisis, it’s not that I’m panicking, but I just keep
my distance due to being afraid of infections because our resistance
is so low.” Several specific infections and related problems
were described such as lung infections, skin infections/disorders,
throat infections, cold, flu, fever, and neutropenia.
Reduced Energy
Reduced energy and related problems, including extreme
tiredness (also described as exhaustion, fatigue, complete lack of
physical strength), sleeping problems, and breathlessness after
minimal activity were discussed extensively. Patients described
that these problems hinder them from performing daily activities,
such as being physically active and independent and hence,
significantly reduce their overall quality of life. Mirroring
patients’ reflections concerning the other side-effects, patients
were afraid of permanent and severely reduced energy problems.
Further, the psychological burden of having no physical strength
and energy was highlighted: “I’m always a very positive person,
but then, my partner was even shocked, that my morale was
below zero.” One patient even mentioned having experienced
such severely reduced energy to the extent of losing the ability
to see clearly.
Pain
Among the several types of pain that MM patients experienced,
the most frequent and severe pains patients discussed were: bone
pain in the back, chest, feet or hips, muscle pain and cramps, for
example in the legs, and nerve pain (sharp, burning, or jabbing
pain caused by nerve damage): “I don’t get up without back pain,
after a walk I also have back pain.” The fear of constant and/or
more severe pain was repeatedly mentioned, as well as the impact
of pain on both the psychological and physical aspects of patients’
life’s: “Due to bone pain, many activities are not possible”; “What
you have to do to feel less pain is find a posture in which you don’t
feel it, because of course, it stops you from doing lots of things.”
Some patients described that there is currently no treatment
(includingmorphine) that alleviates their pain. Similarly, patients
hoped for a treatment that would alleviate or eliminate their
pain, and thereby help them perform their daily activities and
be independent: “Above all, not feeling pain, when doing any
daily activity.” A life without pain, was considered a (more)
normal life: “To be able to have a normal life, without pain.”
One patient described the unbearable pain experienced due to
shingles and post herpetic neuralgia. Some patients also described
episodes of headache on the day of treatment, painful urination,
and extreme stomach aches following stem cell transplantation:
“Severe stomach ache, I felt like I was on fire from the throat
to the rectum.” One patient, however, mentioned to have never
experienced any type of pain: “I’m atypical, in the sense that I
haven’t felt any kind of pain.”
Emotional Problems
Patients raised the following emotional problems: (i) easily
becoming emotional or becoming less emotional (apathetic); (ii)
becoming more aggressive; (iii) feeling depressed; and (iv) feeling
insecure because of changes to your body such as: weight loss,
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weight gain, hair loss, dry eyes, stomach bloating, or abdominal
distention—described by one patient as “9 months pregnant”—
or loss of height due to compressed vertebrae. Patients were
afraid of these problems as these often result in personality
changes, are daily reminders of their cancer diagnosis and may
also prevent patients from doing their daily activities. Several
participants found changes to their body problematic as they had
a negative impact on their emotional well-being: “Because, you
immediately look different, you don’t feel good in your body.” One
patient highlighted that these problems are often considered less
important by “outsiders” in comparison to other, life-threatening
effects: “if you tell the doctors that too, and I understand that too,
then it is seen as slightly less important.” It was not clear whether
depression and becoming emotional were caused by treatment,
the cancer directly, or because of knowing that their life might
end soon. For emotional problems as well, the hope for non-
lasting, temporary problems as opposed to permanent problems
was expressed.
Eating and Digestive Problems
Nausea, vomiting, incontinence, constipation, diarrhea, loss
of appetite, taste changes, and swallowing problems were all
described as problems that significantly reduce patients’ quality
of life. As for other side-effects and symptoms, several patients
were afraid that these problems would become permanent. One
patient noted that these problems are problematic because they
can lead to reduced social contacts. Whether or not patients
had experienced these problems, as well as the severity of
the problems they had experienced, depended on patients’
particular treatment experience. For example, nausea, diarrhea
(and consequently, reduced energy) was linked to treatment with
lenalidomide. Some patients noted the burden of retracting gums
and jaw problems that prevented them from eating properly
and thought these problems were likely due to myeloma rather
than treatments.
Vision Problems
Patients expressed the fear of suffering from (permanent) vision
problems and becoming blind: “I indeed know a number of people
who (. . . ) lost sight. That’s a bit of my biggest fear.” One patient
experienced transient vision changes: “Certainly in the evening,
when I am tired, I can hardly see.” Another patient noted that
his vision problems could be due to treatment with lenalidomide.
However, it remained largely unclear whether vision problems
could be also side-effects of other treatments, due to the cancer
itself or perhaps related to aging. For these problems as well, the
hope for temporary side-effects as opposed to permanent changes
was expressed.
Other Considerations Relevant for
Myeloma Treatment
Preferences Differ According to Patients’ Individual
Characteristics and Experiences
Patients highlighted that their individual preferences were shaped
by their previous treatment and disease experience. Particularly,
whether they had experienced a certain symptom or side-
effect, determined their views and preferences toward those
symptoms and side-effects. Patients more frequently raised those
symptoms and side-effects they had experienced, heard, or seen
with other MM patients than those they or a close contact
had never previously experienced: “When one has gone through
these (side-effects), one can think differently from one who hadn’t
experienced these.” Whereas, frequent symptoms and side-effects
were discussed often, (e.g., bone fractures) others, more new
or rare symptoms, were discussed by one or few patients (e.g.,
vision problems). Aside from treatment and disease experience,
it also appeared that age, working status, whether patients have
carers (such as children) may be important in determining
and understanding why patients place more or less value on
certain treatment characteristics. Further, participants who were
professionally active frequently emphasized the impact of side-
effects that limit their ability to continue working (such as
cognitive problems).
The Burden of Uncertainty
On several occasions patients discussed the psychological burden
of uncertainties including the cause, duration, type, and severity
of side-effects and symptoms: “What can be done about it, is it
treatable or does it mean death? And will stopping (the treatment)
help (. . . )? It’s a terribly awkward thing.” Patients also expressed
difficulty coping with the uncertainty of the duration of their
side-effects and symptoms; patients were afraid that these side-
effects would remain permanent or that the side-effects would
permanently damage organs: “So I am also a bit scared; are there
no side-effects that are permanent, I am of course also a bit scared,
but I still hope that that they really will disappear.” Regarding
uncertainties related to the cause of their problems, patients
discussed that at times they we unsure if their symptoms are
related to treatment or their myeloma. Some participants stated
the importance of managing expectations and that knowing what
side-effects to expect before beginning treatment, is important to
help them decide whether or not to start or continue a treatment:
“If it is known in advance, then it can be decided that I will not
take this treatment because of it.” Participants also underlined
the important role healthcare providers have in addressing these
uncertainties: “Doctors don’t say much about these future side-
effects (. . . ) In fact, I’ve had to find out about things myself (. . . )
Maybe [if I had this information] it would have made it easier to
accept them and to live with them.”
Hope for New Treatments
Increasing life expectancy was also important to patients as some
believed it would increase the chance that during the course
of their disease a new, and ideally curative, MM treatment
would become available. Patients seemed to be motivated by the
knowledge that new treatments are currently being developed
and that perhaps one of the novel therapies would become
available for them, and in time.
Treatability of Side-Effects and Symptoms
Some patients highlighted that when side-effects and symptoms
“can be handled in some way,” they become manageable and
therefore less “important” than side-effects or symptoms for
which no treatments are currently available. For example,
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patients described that severe pains, the development of a new
cancer, and cognitive changes are not treatable with current
drugs, and therefore perceived as being worse: “That is, severe
pain and the onset of another cancer can really be quite difficult.
These problems can be something that can’t be helped at all.”
Risk Tolerance Differed Across Participants
Participants seemed to accept that treatments will always have
side-effects: “No matter what the treatment is, side-effects will
appear. If I would fear the side-effects I would not be undergoing
any treatment.” Naturally, they hoped for these side-effects to
be as few and as mild as possible. However, the severity and
number of risks patients were willing to accept in order to receive
a certain benefit (i.e., their risk tolerance), differed across patients.
Several patients noted that they were willing to accept even
severe side-effects if that would be the condition to continue
treatment. Others described only to be willing to accept severe
side-effects on the condition that the treatment gives noticeable
improvements in their disease.
Sharing Experiences Among Patients
Participants shared positive feedback regarding their
participation in the discussion, they expressed a sense of
comfort knowing that other patients experience similar issues.
Some expressed that they were happy to be able to have
participated in the discussion and share their experiences,
feelings, and thoughts with other myeloma patients. The desire
to continue the discussion after the focus group discussion was
also expressed, as well as the suggestion of gathering via patient
support groups.
DISCUSSION
This study identified treatment and disease-related
characteristics (outcomes, side-effects and symptoms) and
attribute levels that are key factors in determining treatment
attitudes and choices by MM patients. In particular, MM patients
across four European countries and with varying disease and
treatment experience reached consensus on the importance of
the following 11 themes of treatment outcomes, side-effects,
and symptoms: life expectancy, life-threatening side-effects,
treatment response, mobility problems, thinking problems,
infections, reduced energy, pain, emotional problems, eating
and digestive problems, and vision problems. Furthermore,
this study highlights that MM patients are also concerned with
the uncertainties regarding the durability of positive treatment
outcomes, as well as the cause, severity and duration of their
symptoms and side-effects. Regarding the attribute levels, MM
patients feared only short-term positive treatment responses
(benefits) but with permanent and severe side-effects and
symptoms (risks) such as permanent severe pain or permanent
blindness. Finally, this research presents and investigates a
specific qualitative methodology in the context of patient
preference studies, useful to further the methodological field and
enable other researchers to investigate preferences and include
results in decision-making that affects patients.
The attributes identified in this research will benefit
stakeholders to identify priorities and unmet treatment needs
for (new) treatments in MM. Specifically, results from this
study point toward a need for MM treatment that not
only focuses on extending patients’ lives, but as well on
improving those symptoms and side-effects that significantly
impact MM patients’ quality of life. Symptoms and side-effects
explained and valued by patients are: mobility problems, thinking
problems, increased susceptibility to infections, reduced energy,
pain, emotional problems, eating and digestive problems, and
vision problems. Furthermore, this research will inform what
quality of life-related endpoints and outcomes are important
to patients and should therefore be incorporated, in addition
to traditional endpoints (such as progression-free survival and
overall survival), in MM drug development and evaluation.
Examples of HRQoL questionnaires commonly used in myeloma
clinical trials are EORTC QLQ-MY2014, FACT-MM, EORTC-
QLQ-C30, FACT/GOG-Ntx, and MDASI-MM. Among these,
the FACT-MM, EORTC QLQ—MY20, and MDASI-MM are
MM specific scales (i.e., including domains specifically related
to MM) (50, 51). All of the items included in the MM specific
scales were also identified in the current research, which is
an important validation of our study results and vice versa,
validates the work done to identify the items of these MM-
specific scales. However, whereas these scales investigate patients’
experience with these problems, the present study also reveals
how important these problems are for patients, as well as why
they are important and how they impact their lives. Further,
this study reveals the following additional specific aspects of
importance to MM patients, which are not included in all current
MM-specific questionnaires: (i) fear of life-threatening effects,
(ii) instability and strange sensations such as hypersensitivity
of the skin, numbness or reduced physical sensations, (iii)
weakness or stiffness of the legs, feet, toes, and extremities due
to nerve damage, (iv) nerve pain, v) the following physical
changes: weight loss, stomach bloating, loss of height due to
compressed vertebrae, (vi) the following emotional changes:
becoming apathetic, aggressive, depression, (vii) eating and
digestive problems: such as nausea, vomiting, (viii) vision
problems such as blurred vision, (vi) the psychological burden
of coping with uncertainties about the durability of positive
treatment response, the cause, duration, and severity of side-
effects and symptoms.
Some of these additional findings may be explained by the fact
that since the development of the HRQoL questionnaires, novel
treatments with new side-effects and related uncertainties have
been developed and administered to MM patients. For example,
life-threatening neurotoxicity’s and cytokine release syndrome
are new side-effects associated with emerging treatments such
as bispecific T-cell engagers and CAR-T therapies, which
are not captured by previous questionnaires but in this
study were captured in the context of life-threatening side-
effects or side-effects that are so significant that they require
hospitalization for monitoring (37). Further, (recently) approved
drug therapies for MM have been associated with visual changes
such as blurred vision and decrease visual acuity (52). The
identification of these additional items provides a rationale
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for including these aspects in a next revision of the HRQoL
questionnaires. Systematically including the items identified
in this type of research in clinical development, regulatory
benefit-risk assessment, HTA/reimbursement decisions and post-
marketing decisions, could result in a more patient-centric
drug development and evaluation process. Conversely, when
there is no evidence that a MM drug targets any of the
attributes identified in this study, it may be recommended that
such evidence needs to be collected before or after marketing
authorization and/or reimbursement and should subsequently
be taken into account when designing clinical or real-world
evidence research protocols.
This research revealed areas of importance where clear
information about MM treatments is needed to inform
drug development, regulators, HTA bodies, and healthcare
providers. When there is a lack of knowledge and information,
e.g., regarding the long-term effects and their severity, this
uncertainty should be made public, in an accessibly way to
patients. This starts from the clinical trial evidence reported
by the pharmaceutical company toward regulators (in clinical
trial databases, the marketing application and then reported
on the European Public Assessment Report (EPAR), Summary
of Product Characteristics (SmPC) and EMA website), and
downstream when reporting the clinical trial evidence toward
HTA agencies, healthcare providers and patients. MM healthcare
professionals, patients, regulators and HTA bodies/payers should
be able to easily retrieve this information in clinical trial
databases, marketing materials and package inserts of MM
drugs. Accurate and clear information about these aspects and
uncertainties would result in more informed decision-making
by regulators, HTA bodies, physicians and patients. Particularly
in the clinical, individual treatment decision-making between
healthcare providers and patients, transparent communication
before and during treatment may increase patients’ satisfaction
with the treatment decision and motivation to start or continue
a certain treatment and therefore result in better outcomes and
patient quality of life as expectations are managed.
Finally, this study may inform the development of PREFER
recommendations and future guidance regarding patient
preference studies (and methodology) in the context of drug
development and evaluation. More specifically, this study derives
10 experience-based learnings regarding the design, conduct and
analysis of qualitative research aiming to develop attributes and
levels for inclusion in subsequent preference surveys, useful for
the PREFER recommendations and future guidance regarding
patient preference studies (Table 2).
If preference studies are to inform drug development,
regulatory, and reimbursement decisions, it is essential to reflect
on how the key attributes and levels for inclusion in preference
survey were identified. Misspecification of attributes may lead
to biased findings, and hence, biased preference studies, hence
undermining development, regulatory, and reimbursement
decisions. It is therefore important to reflect on how the
characteristics identified in this study compare to those identified
in previous preference studies among MM patients. Comparing
the attributes found in this study to those identified in the
scoping review of previous preference studies (Appendix 2),
reveals that a large portion of these studies used attributes that
were not appointed by patients themselves but developed using
top-down methods, starting from the perspective of researchers,
developers or decision-makers. Previous preference studies have
also used attributes that were associated with one specific therapy.
In contrast, this study identified patient-relevant attributes
across different therapies (for example, novel immunotherapies),
countries and directly from myeloma patients. There are several
potential reasons for differences in attributes identified across
preference studies. Attribute identification, to date, is mostly
done through studies involving literature reviews and qualitative
empirical studies. Qualitative empirical research always requires
contextualizing the results in view of the research setting. This
implies that several factors may differ across qualitative studies,
such as the selected sample, the stakeholder conducting study
(e.g., a patient organization vs. a pharmaceutical company), the
researcher or decision-makers’ interests, the time of study and
the specific questions asked. All of these factors need to be taken
into account when looking at the results (i.e., the identified
attributes) as a difference in any of these may already explain a
difference in the identified attributes. Differences inmethodology
for attribute and level identification are likely triggered by
uncertainties regarding the best methodological approach for
this study type. While the present study derived experience-
based learnings, the methodological field is continuously and
rapidly evolving, and other qualitative study methods are also
under investigation. Combining and comparing experiences
and methodological understanding from different qualitative
approaches will be useful to inform the development of a
standardized approach for use by all stakeholders across disease
areas. Furthermore, methodological understanding will assist
with the development of a validated framework for designing
and conducting preference studies aiming to inform drug
development and evaluation.
Although the attributes reflect areas of consensus, there
was heterogeneity with regards to the value each patient
attached to the attributes. In particular, participants more
frequently valued those symptoms and side-effects they had
previously experienced. Further, participants who were older, had
undergone more treatments, or had no young children seemed
to attach more importance to quality of life related attributes
(such as pain) than life expectancy, and vice versa. Participants
who were professionally active frequently emphasized the
impact of (cognitive) side-effects on their ability to continue
working. Likewise, participants’ willingness to accept more
reduction in quality of life (i.e., symptoms and risk of life-
threatening side-effects) in return for a potential increase
in life expectancy differed across participants, depending on
their individual situation and personal attitudes. These findings
underscore the importance of further quantitative preference
research that statistically substantiates these hypotheses and
provides a quantified understanding of individual patients’
values of life extension vs. symptom reduction vs. risk of life-
threatening side-effects.
The existence of patient subgroups with systematically
different preferences may be viewed both as a challenge and
opportunity from the perspective of decision-makers (industry,
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TABLE 2 | Experience-based learnings regarding the design, conduct, and analysis of qualitative research for informing subsequent quantitative preference surveys in the
context of drug development and evaluation −10 avenues for optimization.
Experience-based learnings regarding qualitative research for informing subsequent quantitative preference surveys
1. Since patients are disease-experts, experiencing the benefits and risks of treatment on a daily basis, they should be systematically and
continuously involved, both as study participants and as study partners.
- The involvement of patients and patient organizations is essential to ensure that the attributes and levels are relevant, comprehensive, and understandable to
patients participating in the subsequent quantitative survey.
- Their involvement throughout the analysis and attribute selection process guarantees that patients’ points of view are reflected in an accurate, unbiased, and
understandable way, and thereby improve the survey validity.
- In return, patients may benefit from learning about treatments obtained through their involvement. Patient organizationsmay benefit from using this methodology
as an evidence-based way to generate data and best represent the patients’ voice.
- The results of preference studies may provide patient organizations an evidence-based perspective when communicating with regulatory and reimbursement
bodies regarding the priorities and needs of patient communities.
2. Before undertaking a preference study, researchers should investigate the availability and usefulness of previous preference studies (qualitative
or quantitative) for informing the attributes and levels for inclusion in their preference survey.
- If previous studies are available in the disease or treatment context of interest, researchers should assess to what extent the attributes and levels of those
studies are transferable and applicable to their research context and aims. This will help determine the necessity of conducting a “new” qualitative study.
- In this study, the goal was to identify attributes and levels relevant to patients with varying treatment exposure, disease history, age, or country of origin. This
contrasted with previously conducted preference studies identified in our scoping review, which only included patients with a specific disease and treatment
experience (e.g., only the relapsed refractory patient population) or used attributes related to a specific treatment. Therefore, a new study considering the
recruitment of patients heterogeneous in terms of treatment experience and disease stage was necessary.
- Preference researchers aiming to identify attributes and levels relevant to patients with various treatment exposures, disease history, age and country of origin
should consider conducting a new qualitative study if a similar qualitative study aiming to pursue this objective is unavailable.
- Furthermore, experience from this study highlights that it is desirable: (i) to include a heterogeneous, inclusive sample of patients in terms of treatment exposure
and disease history as these variables affected patients’ rankings and views, (ii) to include patients from different countries to help ensure a diverse sample of
patients is included.
- Even if a previous preference study with similar aims is available, preference researchers should assess whether the findings of the study are up-to-date,
appropriately designed and comprehensive (i.e., whether they consider novel treatments, as well as related side-effects, outcomes and uncertainties).
3. Researchers should ensure the study is designed to meet the specific needs of the study participants.
- Key decision points which should be tailored toward the particular patient population of interest are the selection of the qualitative data collection method
(the feasibility and usefulness of (telephone) interviews vs. (online) focus group discussions; time, feasibility of ranking exercise) and the development of the
questions (via review and pilot testing to ensure relevance, understandability and accuracy).
- Input from patients, patient organizations, and/or healthcare providers should help ensure the study is designed in such a way that is easiest for the particular
patient population.
- In this study, patients, patient organizations, and healthcare providers confirmed that both individual interviews and focus group discussions would be possible
and agreed that group interaction would be useful between patients and nominal group technique to trigger discussion around the most important treatment
characteristics. In this study, face-to-face discussions were initially planned as myeloma patients are elderly and more likely gravitate away from technology.
- However, future researchers may need to balance the utility of increased interaction via focus group discussions vs. the more practical feasibility of individual
interviews in view of the targeted participant population. For example, interviews allow for more flexibility in choosing various dates for participation and
discussions can take place via telephone and not necessarily online, which is especially relevant in view of COVID19 (and potentially beneficial for elderly
patients or those who are not well-versed in technology).
4. Qualitative studies may also be used to explore which patient variables (such as treatment exposure, disease history, age, or country of origin)
should be useful to inform the quantitative survey.
- In this study, patients highlighted that treatment and disease experience strongly influenced their views.
- Hence, these variables should be collected and used in qualitative and quantitative preference studies to contextualize both the qualitative and quantitative
preference study results.
5. Obtaining input from stakeholders with expertise in the relevant disease and treatment context (patients, patient organizations, healthcare
practioners) and stakeholders with methodological expertise—should help inform the development of attributes and levels.
- Patients can critically reflect on the attributes and levels and thereby avoid inadvertent omittance of attributes and levels of potential importance, as this may
bias findings.
- Clinicians help ensure the attributes and levels are clinically plausible.
- Input from preference research experts helps ensuring the rules of attribute and level development are adhered to.
6. In view of the multitude of methodological choices in attribute and level development, transparently documenting and describing the study
design and methodological choices as well as its limitations and challenges is essential for enabling reviewers to contextualize the study results
and evaluate their usefulness for decision-making.
7. Before starting a preference study, research teams should investigate the necessity of obtaining ethical approval and contractual agreements
with hospitals in all countries where data collection is planned and/or hospitals are involved in data collection, respectively.
- Because ethical approval for this type of research is regulated nationally, researchers should investigate for each country separately, whether the study requires
obtaining ethical approval, and if so, consider the time and administrative burden associated with filing and obtaining ethical approval.
- Experience from this study reveals that the necessity of obtaining ethical approval depends on whether the study is considered in scope of the national law
regulating this type of research. In this study, ethical approval was applied for and obtained in all countries where patients were included. However, during the
submission and approval process, it appeared that the study did not fall in the scope of the national law requiring ethical approval in Belgium and Finland,
where the process of obtaining ethical approval took particularly long. Conversely, the procedure took less time in Spain and Romania, where the ethical
committee did not explicitly mention whether the study required their approval.
(Continued)
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TABLE 2 | Continued
8. Research teams should consider the input, time and administrative burden for involved clinical partners associated with these steps and ensure
flexibility in terms of timelines, if ethical approval, hospital contracts, and patient recruitment relies on their cooperation.
9. Before starting the study, researchers should investigate how patient recruitment and data collection will take place in practice. In this study, the
involvement of oncology nurses and clinicians proved to be crucial for implementing the recruitment and practical organization of the discussions.
10. Preference researchers should consider the practical and methodological implications of COVID19 and/or potential subsequent pandemics
and how their study designs could best meet patient needs.
- In this study, this was especially relevant as myeloma patients have increased susceptibility to infections.
- COVID19 substantially delayed the study, e.g., due to required changes to the initial research protocol to adhere to hospital requirements in view of patient
contact restrictions, and increased workloads for cooperating healthcare professionals, ethical committees and hospital administration offices.
- Future qualitative preference research may likely require digital and online formats for data collection, as well as phone calls, virtual encounters, instead of
face-to-face contacts.
drug developers, and HTA bodies) who develop, authorize and
reimburse drugs for groups of patients and not for individual
patients. In particular, it raises the question whether their
decisions need to be tailored toward specific patient populations
whose preferences align with the product characteristics being
developed or evaluated. The existence of subgroups in the MM
patient population with systematically different relative attribute
values and risk tolerances may also inform the identification
of key areas of unmet needs, benefits and risks for this
relevant population. For example, a company could submit
clinical evidence to apply for marketing authorization and
reimbursement for the elderly, more treatment experienced MM
population (also called the relapsed refractory RRMM) and
clinical trial results may indicate that the treatment causes quality
of life related problems (such as mobility, vision problems) in
this population. If results from a preference study reveal that
this population finds quality of life related attributes (such as
mobility, vision problems) more important than life expectancy,
then decision-makers should likely place more value on these
risks during their assessment of treatment outcomes and ensure
these risks are taken into account during their decision-making.
As for the limitations, it is important to reflect on the
impact of the COVID-19 on this research. This is especially
relevant since this study consisted of qualitative discussions with
MM patients, who have a higher susceptibility to infections.
Conducting this study during COVID-19 required flexibility
from both participants and the study team. For the online and
telephone discussions, it is likely that participants, who were
not comfortable with online discussions or telephone (e.g., older
participants), were less likely to participate. The study team tried
to be as inclusive as possible during recruitment, by offering both
face-to-face and online discussions, according to the preferences
of the participants and the local social distancing and hospital
guidelines. Further, technical support for participants was given
throughout the entire study. A steps-wise guideline explaining
the practicalities of the discussion beforehand, and ensuring
there was an opportunity, before the session, for participants to
test whether they could participate in the discussion. Still, the
median age of diagnosis of patients included in this study was
55, which is 11 years younger than the median age reported by
Kazandijan in 2016 and 14 years younger than the average age
of diagnosis reported by ASCO in 2020 (53, 54). However, there
was a large age range between the youngest and oldest patient
(46–73), and therefore the attributes captured in this study
for inclusion in the next quantitative phase also reflect those
that are most important for elderly patients. Further regarding
generalizability, it is important to note that the purpose of this
study was not to make statements about a population larger than
the included sample. Rather, it aimed to gain in-depth insight into
the opinions of patients participating in the discussions including
which attributes are important to them and why.
Participant heterogeneity in terms of treatment and disease
experience [including the type of treatments received, disease
stage (i.e., refractory level and number of previous treatments,
experienced side-effects)] and demographic characteristics were
introduced to avoid distortions in the data; it was envisioned that
these personal characteristics and experiences could influence
participants’ opinions. Hence, heterogeneity among the focus
group participants, particularly regarding their disease and
treatment experience, triggered interactions between patients
with varying backgrounds and facilitated discussions around
a large range of symptoms, treatment outcomes, and side-
effects, even though some individual participants (earlier
diagnosed, with less treatment experience) had not experienced
them themselves. The inclusion of a heterogeneous group of
participants and their interactions, due to the focus group
methodology, helped ensure that the identified attributes and
levels are not geared to only patients with a particular
background (e.g., with a particular therapy experience, disease
experience, level of education). Likewise, to ensure that patients
would be able to discuss “future” treatment outcomes and side-
effects of novel treatments or treatments under development
(i.e., symptoms they had not yet experienced themselves, such
as those associated with bispecific T-cell engagers and CAR-
T), the focus group discussions included endpoints and adverse
events reported in phase 3MM clinical trials from 2010 onwards
(found in the literature review). Further, the attribute selection
also captured the favorable and unfavorable effects of (recently)
approved MM drug therapies.
The results of this (and other qualitative research) are
time, study context and participant bound and hence need
to be interpreted considering the specific time period and
(drug therapy) context the study took place as well as in
view of the type of participants that took part. For example,
this study took place during COVID19 and this may have
led to the fact that patients more frequently raised their
increased susceptibility to infections. Further, the results should
be viewed in the specific drug therapy context patients are
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experiencing currently; the MM treatment context is rapidly
evolving and a significant number of new and emerging
treatments have been introduced. These novel treatments are
bringing prolonged survival but also potential side-effects
of uncertain severities and duration on the long term. For
example, new treatments such as novel immunotherapies (e.g.,
bispecific T-cell engagers and CAR-T) have been associated
with (acute) side-effects and these may cause psychological
and physical distress to patients. The introduction of these
new therapies and rapidly evolving drug therapy context likely
explains why patients expressed the psychological burden of their
uncertainties related to their side-effects and efficacy outcomes,
particularly regarding treatments only being marketed and
prescribed for a relatively short time period. This study highlights
that patients are concerned with uncertainties regarding the
long-term duration and severity of their side-effects (such as
neuropathic, mobility and vision problems) and about how long
the treatment will continue to work for them. Information
about which uncertainties are most important to patients may
help stakeholders (drug developers, regulators, HTA bodies,
physicians) by providing insights about the uncertainties most
pressing to patients; to be considered during decisions about
evidence generation, marketing authorization, market access and
subsequently managed in the individual treatment decision-
making context.
Several patient characteristics (disease stage such as
refractory level and number of previous treatments), symptom
experience, and demographic data (including country of
origin, health literacy/education) likely influence preferences,
i.e., the value that participant place on attributes (outcomes,
symptoms, and side-effects). For example, MM patients
that are younger, less frail and who have limited treatment
exposure may tolerate and perceive side effects differently.
Therefore, it will be important to investigate, transparently
describe, and consider the impact of these patient variables
on preferences, and to describe this impact as well as their
influence on preferences. Therefore, in the survey following
this qualitative study, we aim to characterize and describe
the demographics of the study population using patient
characteristics when reporting the results. Additionally, in
the follow up quantitative survey, research will focus on
the statistically significant impacts of patient characteristics
on preferences.
CONCLUSION
This study gained an in-depth understanding of the treatment
and disease-related characteristics (outcomes, side-effects, and
symptoms) and types of attribute levels (severity, duration) that
are most important to MM patients. Results point toward a
need for MM drug development, evaluation, and individual
treatment decision-making that not only focuses on extending
patients’ lives, but that addresses symptoms and side-effects that
significantly impact MM patients’ quality of life. This study
underlines the need for communication toward patients about
the short and long-term effects of MM treatments. Finally, this
study may help stakeholders to understand which quality of life-
related treatment outcomes are most important to MM patients
and therefore should be considered for systematic incorporation
in MM drug development, evaluation and clinical practice.
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